Phaseline

Targets › RYR2

RYR2 (Ryanodine receptor 2): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Cardiovascular; next expected readout Jun 2027.

Cytosolic calcium-activated calcium channel that mediates the release of Ca(2+) from the sarcoplasmic reticulum into the cytosol and thereby plays a key role in triggering cardiac muscle contraction. Aberrant channel activation can lead to cardiac arrhythmia. (UniProt, Q92736)

Open in Phaseline: the race on RYR2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Solid BiosciencesSGT-501
Gene therapy for ryanodine receptor 2 (RYR2) deficiency
RYR2Phase 1Catecholaminergic Polymorphic Ventricular TachycardiaJun 2027

Conditions

Catecholaminergic Polymorphic Ventricular Tachycardia (1)

Modalities

small molecule (1)

Companies

Solid Biosciences (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.